Zach Taiji's Wiki

Company Mentions:
- LEO Pharma unveils up to 250 layoffs and relocations amid CEO’s revamp. In an article in MedWatch, an HR and recruitment specialist is concerned that new senior employees will be hard to find for LEO Pharma, after the recent layoffs.
- LEO Pharma submits a New Drug Application (NDA) to China’s National Medical Products Administration for Enstilar, targeting the treatment of adult patients with plaque psoriasis.
tralokinumab (ADBRY):
- Over 70% of patients with AD maintained stable Eczema Area and Severity Index (EASI) scores ≤ 7 for at least 80% of days with long-term tralokinumab treatment, as shown in the ECZTEND trial presented at the EADV 2024 congress.
- Also presented during the event, 9 months of tralokinumab treatment significantly improved itch, sleep quality, and overall quality of life in adult patients with AD, according to interim results from the TRACE study.
- In the Dermatology Digest, April Armstrong, MD, Professor and Chief of Dermatology at University of California-Los Angeles (UCLA), shares interim results from the TRACE study.
delgocitinib:
- At EADV 2024, two studies suggest that topical delgocitinib may be more effective than oral alitretinoin for treating CHE, comparable to subcutaneous dupilumab.

Incyte expands its Moments of Clarity educational AD program, with the addition of new patient stories centered around its OPZELURA cream.
A dermatologist outlines strategies for managing pediatric AD, highlighting the importance of simplifying treatment regimens for better adherence and offering advanced therapies like dupilumab and tralokinumab for severe cases.
Thermo Fisher Scientific launches its international CorEvitas Adolescent AD Registry, designed to study novel treatments for the most common inflammatory skin condition in adolescent patients.
The ARCADIA trial finds that nemolizumab improves signs and symptoms of AD up to 56 weeks in adolescents and adults, presented at EADV 2024.
ClinicalTrials Arena summarizes the FDA’s recent approval of EBGLYSS for AD, positioning it as a key competitor to ADBRY and DUPIXENT. According to analysts, EBGLYSS will require strategic market positioning to differentiate it against the competition.
A new study finds Dupulimab was safe and effective for treating AD in youth with inborn errors of immunity.
AbbVie hosts “The Eczema Experience: Stories Itching to Be Told” in New York City, featuring personal stories and expert insights from eczema advocate Tia Mowry and dermatologist-psychiatrist Dr. Evan Rieder.

Dr. Reddy’s Laboratories

Company Mentions:
- Dr. Reddy’s signs a voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
denosumab:
- The European Medicines Agency (EMA) accepts STADA’s filing for AVT03, a proposed denosumab biosimilar.
- TVB-009P, Teva’s proposed biosimilar to Prolia, is accepted for review by the FDA and the EU’s EMA.
- A new study is published, “Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years”.

omadacycline (NUZYRA):
- The phase 3 study of NUZYRA meets all primary and secondary endpoints for treating moderate to severe CABP. Label update discussions with the FDA are expected to begin by Q4 2024.
- A patient case report of acute pancreatitis, possibly induced by omadacycline, is published in BMC.
- Paratek celebrates six years since the FDA’s approval of NUZYRA.